Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
出版年份 2020 全文链接
标题
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
作者
关键词
-
出版物
Cancers
Volume 12, Issue 2, Pages 319
出版商
MDPI AG
发表日期
2020-02-03
DOI
10.3390/cancers12020319
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- In search of definitions: Cancer-associated fibroblasts and their markers
- (2019) Martin Nurmik et al. INTERNATIONAL JOURNAL OF CANCER
- Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer
- (2019) Tessa P. Sandberg et al. BMC CANCER
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- (2019) A B Schrock et al. ANNALS OF ONCOLOGY
- Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
- (2019) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS
- (2019) Elizabeth Alwers et al. BMC CANCER
- BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study
- (2019) Leo Mas et al. Cancers
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
- (2019) Michael A. Morse et al. ONCOLOGIST
- 125PTumour mutation burden and microsatellite instability in colorectal cancer
- (2019) F Fenizia et al. ANNALS OF ONCOLOGY
- LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
- (2019) J Taieb et al. ANNALS OF ONCOLOGY
- Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
- (2019) Ibrahim Halil Sahin et al. BRITISH JOURNAL OF CANCER
- The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
- (2019) Mifanwy Reece et al. Frontiers in Genetics
- Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis
- (2019) FAUSTO PETRELLI et al. ANTICANCER RESEARCH
- MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis
- (2019) Moxin Wu et al. PATHOLOGY RESEARCH AND PRACTICE
- Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study
- (2018) Julia Bergheim et al. BRITISH JOURNAL OF CANCER
- The Association Between Mutations in BRAF and Colorectal Cancer–Specific Survival Depends on Microsatellite Status and Tumor Stage
- (2018) Hendrik Bläker et al. Clinical Gastroenterology and Hepatology
- Colorectal Cancer: Why Does Side Matter?
- (2018) Claire Gallois et al. DRUGS
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines
- (2018) Ricarda Herr et al. ONCOGENE
- PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
- (2018) Qiang Wang et al. Cell Death & Disease
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
- (2018) C M Parseghian et al. ANNALS OF ONCOLOGY
- Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis
- (2018) Yasuyuki Shigematsu et al. BMC CANCER
- A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells
- (2018) Giulia Cesi et al. Molecular Cancer
- Immunotherapy for colorectal cancer: where are we heading?
- (2017) Debora Basile et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Colorectal cancer-global burden, trends, and geographical variations
- (2017) Jeffrey Douaiher et al. JOURNAL OF SURGICAL ONCOLOGY
- Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
- (2017) Kaja C. G. Berg et al. Molecular Cancer
- Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer
- (2017) Claudio Isella et al. Nature Communications
- Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial
- (2017) Siân Pugh et al. Oncotarget
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer
- (2017) Sabine Tejpar et al. JAMA Oncology
- Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer
- (2017) Fausto Petrelli et al. JAMA Oncology
- Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
- (2016) D. P. Modest et al. ANNALS OF ONCOLOGY
- Prognostic role of tumorPIK3CAmutation in colorectal cancer: a systematic review and meta-analysis
- (2016) Z. B. Mei et al. ANNALS OF ONCOLOGY
- The evolving role of microsatellite instability in colorectal cancer: A review
- (2016) Fabio Gelsomino et al. CANCER TREATMENT REVIEWS
- BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
- (2016) David Barras et al. CLINICAL CANCER RESEARCH
- Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
- (2016) E. Yakirevich et al. CLINICAL CANCER RESEARCH
- Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
- (2016) Etienne Becht et al. CLINICAL CANCER RESEARCH
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
- (2016) Bernhard Mlecnik et al. IMMUNITY
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- From tumour heterogeneity to advances in precision treatment of colorectal cancer
- (2016) Cornelis J. A. Punt et al. Nature Reviews Clinical Oncology
- CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
- (2016) Piero Dalerba et al. NEW ENGLAND JOURNAL OF MEDICINE
- How the Lab is Changing Our View of Colorectal Cancer
- (2016) Chiara Cremolini et al. TUMORI
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
- (2016) C. Alix-Panabieres et al. Cancer Discovery
- Hypoxia-responsive miR-210 promotes self-renewal capacity of colon tumor-initiating cells by repressing ISCU and by inducing lactate production
- (2016) Pit Ullmann et al. Oncotarget
- Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models
- (2016) Zsófia Sztupinszki et al. Scientific Reports
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- How the Lab is Changing Our View of Colorectal Cancer
- (2016) Chiara Cremolini et al. TUMORI JOURNAL
- Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
- (2015) Alessio Amatu et al. BRITISH JOURNAL OF CANCER
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
- (2015) A Rowland et al. BRITISH JOURNAL OF CANCER
- Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: A p53 Research Group study
- (2015) N. Pilat et al. EJSO
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
- (2015) Frank A. Sinicrope et al. GASTROENTEROLOGY
- Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer
- (2015) John M. Carethers et al. GASTROENTEROLOGY
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors
- (2015) S. Kopetz et al. ONCOLOGIST
- MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab
- (2015) Jitka Mlcochova et al. Oncotarget
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- Chemotherapy for Stage II Colon Cancer
- (2015) Anna Varghese Clinics in Colon and Rectal Surgery
- TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients
- (2015) Daniela Kandioler et al. EBioMedicine
- A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer
- (2015) Mireia Berdiel-Acer et al. Oncotarget
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
- (2014) H. Blons et al. ANNALS OF ONCOLOGY
- Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer
- (2014) E Letellier et al. BRITISH JOURNAL OF CANCER
- KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
- (2014) H. H. Yoon et al. CLINICAL CANCER RESEARCH
- Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
- (2014) G. Manceau et al. CLINICAL CANCER RESEARCH
- Non-muscle myosins in tumor progression, cancer cell invasion, and metastasis
- (2014) Jessica L. Ouderkirk et al. Cytoskeleton
- CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer
- (2014) Stacey Shiovitz et al. GASTROENTEROLOGY
- Current Status of Gene Expression Profiling to Assist Decision Making in Stage II Colon Cancer
- (2014) Cheng E. Chee et al. ONCOLOGIST
- Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer
- (2013) Matthias Maak et al. ANNALS OF SURGERY
- The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis
- (2013) Josh J. Carlson et al. BREAST CANCER RESEARCH AND TREATMENT
- The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
- (2013) V Eklöf et al. BRITISH JOURNAL OF CANCER
- Anticipating the Clinical Use of Prognostic Gene Expression-Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?
- (2013) A. Sveen et al. CLINICAL CANCER RESEARCH
- BRAFmutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis
- (2013) C. Clancy et al. Colorectal Disease
- Patients With Colorectal Tumors With Microsatellite Instability and Large Deletions in HSP110 T17 Have Improved Response to 5-Fluorouracil–Based Chemotherapy
- (2013) Ada Collura et al. GASTROENTEROLOGY
- Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
- (2013) Frank A. Sinicrope et al. JOURNAL OF CLINICAL ONCOLOGY
- Correction: Comparison of Prognostic Genomic Predictors in Colorectal Cancer
- (2013) Yun-Yong Park et al. PLoS One
- BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients’ Outcome
- (2013) Zacharenia Saridaki et al. PLoS One
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
- (2013) Laetitia Marisa et al. PLOS MEDICINE
- Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma
- (2012) Peter F. Lenehan et al. CANCER
- Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
- (2012) Y. Imamura et al. CLINICAL CANCER RESEARCH
- ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients
- (2012) A. Sveen et al. CLINICAL CANCER RESEARCH
- Biomarker Failures
- (2012) J. P. A. Ioannidis CLINICAL CHEMISTRY
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
- (2012) Trude H Ågesen et al. GUT
- Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
- (2012) Paola Ulivi et al. Journal of Translational Medicine
- Cancer classification using the Immunoscore: a worldwide task force
- (2012) Jérôme Galon et al. Journal of Translational Medicine
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
- (2012) Gholamreza Safaee Ardekani et al. PLoS One
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF
- (2012) Neda Mosakhani et al. Cancer Genetics
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?
- (2011) Robin K. Kelley et al. Clinical Colorectal Cancer
- The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer
- (2011) Sung Pil Hong et al. EUROPEAN JOURNAL OF CANCER
- Molecular profiles and clinical outcome of stage UICC II colon cancer patients
- (2011) Jörn Gröne et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
- (2011) Richard D. Kennedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA methylation predicts recurrence from resected stage III proximal colon cancer
- (2010) Joong Bae Ahn et al. CANCER
- Fit-for-purpose biomarker method validation in anticancer drug development
- (2010) Jeffrey Cummings et al. DRUG DISCOVERY TODAY
- Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data
- (2010) Cecilia Guastadisegni et al. EUROPEAN JOURNAL OF CANCER
- Microsatellite Instability in Colorectal Cancer
- (2010) C. Richard Boland et al. GASTROENTEROLOGY
- Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin
- (2010) Michael J. O'Connell et al. JOURNAL OF CLINICAL ONCOLOGY
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
- (2010) Ramon Salazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
- (2010) Chen Mao et al. MOLECULAR BIOLOGY REPORTS
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarker method validation in anticancer drug development
- (2007) J Cummings et al. BRITISH JOURNAL OF PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search